CAMX Camurus AB (publ)

72.92USD739.50 SEK · STO-0.07%Mkt Cap: 4.34B USDP/E: 58.69

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphi…

Institutional holders10 on file

Key Statistics

Company
Market Cap4.34B USD
Enterprise Value3.92B USD
Revenue (TTM)238.99M USD
Gross Profit207.99M USD
Net Income (TTM)72.53M USD
Revenue/Share4.00 USD
Last Price72.92 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees323
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0007692850
Valuation
P/E (Trailing)58.69
P/E (Forward)48.05
PEG—
EV/EBITDA43.47
EV/Revenue16.42
P/S18.16
P/B8.85
EPS (TTM)1.24 USD
EPS (Forward)1.52 USD
52W Range
42.4897% of range73.96
52W High73.96 USD
52W Low42.48 USD
Profitability
Gross Margin93.11%
Oper. Margin37.42%
EBITDA Margin37.77%
Profit Margin32.47%
ROE17.37%
ROA15.52%
ROIC111.93%
ROCE19.98%
Growth
Revenue Growth27.70%
Earnings Growth39.80%
Cash Flow & Leverage
Operating CF85.72M USD
CapEx (TTM)13.66M USD
FCF Margin25.15%
FCF Yield1.38%
Net Debt-418.73M USD
Net Debt/EBITDA-4.64
Net Debt/FCF-6.97
Balance Sheet
Debt/Equity0.03
Current Ratio9.65
Quick Ratio9.03
Book Value/Sh8.24 USD
Cash/Share7.21 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)83.82 USD
Upside (mean)+14.9%
Target Range73.46 USD – 95.16 USD
73.46+14.9% to mean95.16
# Analysts8
Ownership
Shares Out.59.51M
Float39.45M
Insiders33.12%
Institutions43.80%
Technical
SMA 5064.54 (+13.0%)
SMA 20056.49 (+29.1%)
Beta0.42
S&P 52W Chg12.00%
Avg Vol (30d)95.10K
Avg Vol (10d)142.05K
Technical Indicators
RSI (14)67.9
MACD24.2749
MACD Signal24.2647
MACD Hist.+0.0102
BB Upper76.42 USD
BB Middle69.88 USD
BB Lower63.35 USD
BB Width18.71%
ATR (14)1.788 USD
Vol Ratio (20d)0.69x

About Camurus (STO: CAMX)

›

Camurus (STO: CAMX) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 323 employees.

The shares were at 739.50 SEK on 20 November 2026, up 21.0% over 52 weeks. Its 52-week range is 430.80 SEK to 750.00 SEK: the price is 1.4% below the high and 71.7% above the low.

At a market capitalisation of 44.01B SEK, it trades at 58.7 times trailing earnings and 48.1 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a premium of 77% for CAMX.

Camurus reports return on equity of 17.4%, an operating margin of 37.4% and revenue up 27.7% year over year.

It holds more cash than debt, a net cash position of 4.25B SEK. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 8 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 850.00 SEK is 14.9% above the current price. The next earnings report is expected on 11 February 2027.